相似文献
1
Switching haemophilia products and inhibitor risk: a United States' perspective.
Eur J Haematol. 2015 Apr;94(4):283. doi: 10.1111/ejh.12441.
2
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15.
3
An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Haemophilia. 2011 Sep;17(5):771-6. doi: 10.1111/j.1365-2516.2011.02599.x. Epub 2011 Jun 20.
4
The management of hemophilia patients with inhibitors.
Transfus Med Rev. 1992 Oct;6(4):285-93. doi: 10.1016/s0887-7963(92)70185-0.
5
Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Thromb Haemost. 1999 Aug;82(2):531-9.
6
Key issues in inhibitor management in patients with haemophilia.
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s319-29. doi: 10.2450/2013.0246-12. Epub 2013 Dec 3.
7
Inhibitor eradication with rituximab in haemophilia: where do we stand?
Br J Haematol. 2014 Jun;165(5):600-8. doi: 10.1111/bjh.12829. Epub 2014 Mar 15.
8
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Br J Haematol. 2006 Jun;133(6):591-605. doi: 10.1111/j.1365-2141.2006.06087.x.
9
Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Prog Clin Biol Res. 1990;324:69-78.
10
Recombinant clotting factors in the treatment of hemophilia.
Thromb Haemost. 1999 Aug;82(2):516-24.
引用本文的文献
1
Emicizumab state-of-the-art update.
Haemophilia. 2022 May;28 Suppl 4(Suppl 4):103-110. doi: 10.1111/hae.14524.
Zotero 插件